Susanna Naggie
Maria Buti
Stanislas Pol
Jürgen Rockstroh
HCV-trials.com Experts Committee
Stay Up To date. Experts commentary
Extrahepatic Cancers Are the Leading Cause of Death in Patients Achieving Hepatitis B Virus Control or Hepatitis C Virus Eradication.20/11/2018 - by François Raffi
Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES.25/01/2018 - by Alessandra Mangia
Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus.
15/01/2018 - by Maria Buti 
Statins decrease the risk of decompensation in HBV- and HCV-related cirrhosis: a population-based study.
28/09/2017 - by Susanna Naggie 
DAA-associated HBV reactivation: from the warning to the daily practice - To treat or not to treat
16/08/2017 - by Stanislas Pol
American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection.19/07/2017 - by François Raffi
Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.05/07/2017 - by Alessandra Mangia
Infection With Hepatitis C Virus Genotype 3 Is an Independent Risk Factor for End-Stage Liver Disease, Hepatocellular Carcinoma, and Liver-Related Death
20/06/2017 - by Stanislas Pol 
Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia.10/05/2017 - by Jordan Feld
Direct-acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-induced Cryoglobulinemia Vasculitis.10/05/2017 - by Jordan Feld
Efficacy and Safety of Sofosbuvir plus Daclatasvir for Treatment of HCV-associated Cryoglobulinemia Vasculitis.10/05/2017 - by Jordan Feld
